Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Paliperidone palmitate - ERZOFRI
Product / population
Adult ERZOFRI injection; product-specific renal initiation and maintenance only.
Renal method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source revision
Prescribing information revised 03/2025.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ERZOFRI: product-specific initiation is not the SUSTENNA schedule
The retrieved RX and exact DailyMed renal passages agree on ERZOFRI initiation and monthly maintenance. A mirror plus its underlying label is one label family, not independent corroboration.
What to reconcile: Keep ERZOFRI initiation, maintenance, switching and missed-dose instructions together; do not add a Day-8 injection from a different paliperidone product.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR. Source date: Prescribing information revised 03/2025. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At Cockcroft-Gault CrCl 50 to <80 mL/min, give 234 mg on Day 1 in the deltoid, then 78 mg monthly in the deltoid or gluteal muscle. Maintenance may be adjusted to 39, 78, 117 or 156 mg; the renal maximum is 156 mg monthly. Use is not recommended below CrCl 50. This is not the SUSTENNA two-injection initiation schedule; no Day-8 ERZOFRI dose is added by this application. Switching and missed-dose instructions require their own full product protocol.
RDM45-official-paliperidone-erzofri-202ef58819-C1 · Source locator: Sections 2.4 and 8.6; lines 423-426 and 1010-1012. PI revision 03/2025 at line 250.
Source-specific limits
Exact DailyMed Set ID discovered through its official results page, not a guessed label URL. RX mirror and official label are not independent validation votes.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.